It Seems Precision Therapeutics Inc. (AIPT) Will Go Down. Formed A Few Months Multiple Bottom Chart Pattern

July 14, 2018 - By Michael Garrison

The stock of Precision Therapeutics Inc. (AIPT) shows a multiple bottoms pattern with $1.20 target or 8.00 % below today’s $1.30 share price. The 5 months chart pattern indicates high risk for the $15.35M company. It was reported on Jul, 14 by If the $1.20 price target is reached, the company will be worth $1.23 million less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock increased 4.00% or $0.05 during the last trading session, reaching $1.3. About 3.64M shares traded or 1177.20% up from the average. Precision Therapeutics Inc. (NASDAQ:AIPT) has declined 41.62% since July 14, 2017 and is downtrending. It has underperformed by 54.19% the S&P500.

More notable recent Precision Therapeutics Inc. (NASDAQ:AIPT) news were published by: which released: “Precision Therapeutics Granted European Patent for its Automated, Direct-to-Drain Medical Fluid Disposal System” on July 13, 2018, also with their article: “30 Stocks Moving In Friday’s Mid-Day Session” published on July 13, 2018, published: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” on June 29, 2018. More interesting news about Precision Therapeutics Inc. (NASDAQ:AIPT) were released by: and their article: “Precision Therapeutics Signs Definitive Merger Agreement with Helomics Holding Corporation” published on June 28, 2018 as well as‘s news article titled: “Breaking Medical Stock News: AIPT Signs Definitive Merger Agreement with Helomics” with publication date: July 11, 2018.

Precision Therapeutics Inc. engages in the development of a healthcare contract research organization that provides personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries. The company has market cap of $15.35 million. The company's CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. It currently has negative earnings. It also produces STREAMWAY System for automated and direct-to-drain medical fluid disposal.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.